Yan Jia-Wang, Nie Mei, Zhang Hang, Liu Yan-Miao, Tang Fu-Shan
Department of Clinical Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China.
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563006, Guizhou Province, China.
World J Gastroenterol. 2025 Mar 7;31(9):100607. doi: 10.3748/wjg.v31.i9.100607.
Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, manifests as a chronic, recurrent, and refractory intestinal inflammatory condition significantly impacting patients' quality of life. Despite ongoing research, its etiology and pathogenesis remain incompletely understood. Recent advancements in medical research highlight the critical role of drug combination therapies in managing IBD. This paper employs the strengths, weaknesses, opportunities, and threats framework to evaluate the four strategic elements (strengths, weaknesses, opportunities, and threats) pertaining to combination therapies for IBD. Among the strengths, the paper underscores the efficacy of multi-targeted strategies, the advancement of personalized medicine, and the mitigation of drug resistance. Nonetheless, the analysis identifies significant weaknesses, including the prohibitive cost of treatment, issues with patient compliance, and the necessity for comprehensive long-term safety data. The paper also delineates opportunities to augment therapeutic success through the incorporation of biomarkers, the application of artificial intelligence, and extensive international collaborative efforts. In contrast, the paper does not shy away from addressing the threats, which include the potential for therapeutic resistance and the logistical challenges inherent in global therapy deployment. These initiatives aim to refine future therapeutic practices, fostering safer, more effective, and personalized treatment paradigms for IBD patients.
炎症性肠病（IBD），包括克罗恩病和溃疡性结肠炎，表现为一种慢性、复发性和难治性肠道炎症性疾病，严重影响患者的生活质量。尽管研究不断，但对其病因和发病机制仍未完全了解。医学研究的最新进展凸显了联合药物疗法在IBD治疗中的关键作用。本文采用优势、劣势、机会和威胁框架来评估与IBD联合疗法相关的四个战略要素（优势、劣势、机会和威胁）。在优势方面，本文强调了多靶点策略的疗效、个性化医疗的进展以及耐药性的减轻。然而，分析发现了一些重大劣势，包括治疗成本高昂、患者依从性问题以及全面长期安全性数据的必要性。本文还阐述了通过纳入生物标志物、应用人工智能以及广泛的国际合作努力来提高治疗成功率的机会。相比之下，本文也不回避应对威胁，其中包括治疗耐药性的可能性以及全球治疗部署中固有的后勤挑战。这些举措旨在完善未来的治疗实践，为IBD患者培育更安全、更有效和个性化的治疗模式。
